Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

2013328 citationsJournal Articlehybrid Open Access

Authors

Daniel J. Wallace · University of California, Los Angeles

Kenneth Kalunian · University of California, San Diego

Michelle Petri · Johns Hopkins Medicine

Vibeke Strand · Stanford University

Frédéric Houssiau · Cliniques Universitaires Saint-Luc

Marilyn C. Pike · Massachusetts General Hospital

B. Kilgallen

Abstract

Treatment with epratuzumab 2400 mg cd was well tolerated in patients with moderately to severely active SLE, and associated with improvements in disease activity. Phase III studies are ongoing.

Topics & Keywords

Systemic Lupus Erythematosus Research T-cell and B-cell Immunology Monoclonal and Polyclonal Antibodies Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of the Rheumatic Diseases

Volume 73, Issue 1, pp. 183-190

DOI: 10.1136/annrheumdis-2012-202760

Field-Weighted Citation Impact: 35.04